


Amendments to the Claims

This claim listing will replace all prior versions of claims and claim listings in the  
 5 application:

WHAT IS CLAIMED:

1. (Currently amended) A compound structurally represented by Formula I





Formula (I)

10 or pharmaceutically acceptable salts thereof wherein:


R¹ is

-CH₂N R³R⁴,

-CONR³R⁴,



15



R² is

-Hydrogen,


-NH-(C₁-C₆) alkyl,


20

-NH-(C₁-C₄) alkylene-phenyl,

-NH(C₃-C₆)cycloalkyl,

-NR³R⁴,





wherein;

$R^3$  is hydrogen,

5                     $-(C_1-C_4)$  alkyl,

$R^4$  is

$-(C_1-C_4)$  alkyl,

$-(C_1-C_4)$  alkylene -phenyl,

10            wherein  $R^3$  and  $R^4$  can cyclize to form, together with the nitrogen to which they  
are attached, a five or six-membered ring, wherein optionally one of the carbons of  
the ring formed by said nitrogen,  $R^3$ , and  $R^4$ , is replaced by a nitrogen or oxygen,  
and wherein said ring is optionally further substituted by  $R^5$ , and


$R^5$  is hydrogen,

15             $-(C_1-C_4)$  alkyl, wherein optionally  $R^5$  forms a 3 to five membered ring  
with the nitrogen containing ring to which it is attached,

$-(C_1-C_4)$  alkylene -N-pyrrolidinyl,


$-(C_1-C_4)$  alkylene -N- piperidinyl;

provided that when  $R^1$  is  $-CH_2N R^3 R^4$  or  $-CONR^3 R^4$ , then  $R^2$  is



20

2. (Original) A compound structurally represented by Formula II,



(II)

or pharmaceutically acceptable salts thereof wherein:

Z is -carbonyl-, or -CH<sub>2</sub>-,

5 R<sup>2</sup> is


-Hydrogen,

-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl,

-NH-(C<sub>1</sub>-C<sub>4</sub>) alkylene-phenyl,

-NH(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

10 -NR<sup>3</sup>R<sup>4</sup>,



wherein;

15 R<sup>3</sup> is hydrogen,

-(C<sub>1</sub>-C<sub>4</sub>) alkyl,

R<sup>4</sup> is

-(C<sub>1</sub>-C<sub>4</sub>) alkylene -phenyl,

20 wherein R<sup>3</sup> and R<sup>4</sup> can cyclize to form, together with the nitrogen to which they are attached, a five or six-membered ring, wherein optionally one of the carbons of the ring formed by said nitrogen, R<sup>3</sup>, and R<sup>4</sup>, is replaced by a nitrogen or oxygen, and wherein said ring is optionally further substituted by R<sup>5</sup>, and

R<sup>5</sup> is hydrogen,

-(C<sub>1</sub>-C<sub>4</sub>) alkyl, wherein optionally R<sup>5</sup> forms a 3 to five membered ring with the nitrogen containing ring to which it is attached,

-(C<sub>1</sub>-C<sub>4</sub>) alkylene -N-pyrrolidinyl,

5       -(C<sub>1</sub>-C<sub>4</sub>) alkylene -N- piperidinyl.

3. (Original) The compound of claim 1, wherein R<sup>1</sup> is CONR<sup>3</sup>R<sup>4</sup>, and R<sup>3</sup> and R<sup>4</sup> cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by -CH<sub>2</sub>- pyrrolidinyl.


10       4. (Original) The compound of claim 1, wherein R<sup>1</sup> is CH<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, and R<sup>3</sup> and R<sup>4</sup> cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by -CH<sub>2</sub>- pyrrolidinyl.

5. (Original) The compound of claim 3 wherein R<sup>2</sup> is N R<sup>3</sup>R<sup>4</sup>, and R<sup>3</sup> and R<sup>4</sup> cyclize to form, together with the nitrogen to which they are attached, a five membered ring.






15       6. (Original) The compound of claim 4 wherein R<sup>2</sup> is N R<sup>3</sup>R<sup>4</sup>, and R<sup>3</sup> and R<sup>4</sup> cyclize to form, together with the nitrogen to which they are attached, a five membered ring.







7. (Currently amended) The compound of claim 1, further represented by any one of the formula (Example 1) to (Example 18) selected from the group consisting of:


20

Example Number	
1	



7	
8	
9	
10	
11	





12	
13	
14	
15	
16	
17	



or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

8. (Currently amended) A pharmaceutical composition which comprises a compound of ~~any of~~ claims 1-7 and a pharmaceutically acceptable carrier.
- 5 9. (Currently amended) A method for treatment or prevention of a cognitive disorder which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of~~ Claims 1-7.
10. (Original) The method of Claim 9 wherein the antagonist is a pharmaceutical composition of claim 8.
- 10 11. (Currently amended) A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of~~ Claims 1-7.
12. (Original) The method of Claim 11 wherein the antagonist is a pharmaceutical composition of claim 8.
- 15 13. (Currently amended) A method for treatment or prevention of a wakefulness disorder which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of~~ Claims 1-7.
14. (Original) The method of Claim 13 wherein the antagonist is a pharmaceutical composition of claim 8.
- 20 15. (Canceled).
16. (New) A compound selected from the group consisting of:



Example Number	
7	 <chem>C1CCN1c2ccc(cc2C(=O)NCC3=CC=CC=C3)C(=O)C(F)(F)F</chem>
10	 <chem>CN1CCN(C1)c2ccc(cc2C(=O)N3CCN4C3CCN4)C5=CC=CC=C5</chem>
11	 <chem>CN1CCN(C1)c2ccc(cc2C(=O)NCC3CCN3)C4=CC=CC=C4</chem>
12	 <chem>CN1CCN(C1)c2ccc(cc2C(=O)N3CCN(C4=CC=CC=C4)CC3)C5=CC=CC=C5</chem>

or a pharmaceutically acceptable salt thereof.